Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 12,070 | 15,795 | 8,249 | 11,333 | 10,078 |
| Marketable Securities | N/A | 6 | 24 | 42 | 57 |
| Receivables | 68 | 58 | 250 | 70 | 232 |
| Other current assets | 0 | 0 | 210 | 179 | 0 |
| TOTAL | $14,848 | $16,318 | $9,186 | $11,920 | $10,716 |
| Non-Current Assets | |||||
| Intangibles | 288 | 293 | 307 | 316 | 314 |
| TOTAL | $288 | $293 | $307 | $316 | $314 |
| Total Assets | $15,136 | $16,611 | $9,493 | $12,236 | $11,030 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,285 | 3,333 | 3,924 | 3,775 | 3,135 |
| Other current liabilities | 6,812 | 10,783 | 7,680 | 9,083 | 6,871 |
| TOTAL | $11,097 | $14,123 | $11,628 | $12,900 | $10,063 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $11,097 | $14,123 | $11,628 | $12,900 | $10,063 |
| Shareholders' Equity | |||||
| Common Shares | 78,643 | 73,716 | 65,682 | 63,926 | 57,391 |
| Retained earnings | -108,197 | -105,039 | -87,003 | -83,298 | -73,893 |
| Other shareholders' equity | 33,593 | 33,811 | 19,185 | 18,708 | 17,469 |
| TOTAL | $4,039 | $2,488 | $-2,135 | $-664 | $968 |
| Total Liabilities And Equity | $15,136 | $16,611 | $9,493 | $12,236 | $11,030 |